Breast Cancer
B47 Chemo+-Trastuz HER2low Adj Breast
A Randomized Phase III Trial of Adjuvant Therapy
Comparing Chemotherapy Alone (Six Cycles of Docetaxel
Plus Cyclophosphamide or Four Cycles of Doxorubicin
Plus Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women with Node-Positive
or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Hematological
Signature Series: PI3K Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients
with Pathway Activated Tumors: Module 1 - Bkm120 For
Patients With PI3K-Activated Tumors
Signature Series: FGFR Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients
with Pathway Activated Tumors: Module 2 - Dovitinib for
Patients with Tumor Pathway Activations Inhibited by
Dovitinib Including tumors with Mutations or Translocations
of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFRI, Trk and RET

Leukemia
CML Observational Trial - SIMPLICITY
Studying Interventions for Managing Patients with Chronic
Myeloid Leukemia in Chronic Phase: The 5-Year Prospective
Cohort Study (SIMPLICITY)

Azacitidine+BSC vs BSC AML Remission
A Phase III, Randomized, Double-Blind, Placebo-Controlled
Study to Compare Efficacy and Safety of Oral Azacitidine
Plus Best Supportive Care Versus Best Supportive Care
as Maintenance Therapy in Subjects with Acute Myeloid
Leukemia in Complete Remission

SGN-35 CD30+ Non-Lymphoma Malignancies
A Phase II, Open-Label, Single-Arm Study of Brentuximab Vedotin
in Patients with CD30-Positive Nonlymphomatous Malignancies

Nilot Discon- CML Pts in MMR on imat>1yr
A Phase II Randomized, Multicenter Study of Treatment-Free
Remission inChronic Myeloid Leukemia in Chronic Phase
(CML-CP) Patients Who Achieve and Sustain MR4.5 After
Switching to Nilotinib

Lung
LDK378 v SOC ALK+ NSCLC Post Chemo/Criz
A Phase III, Multicenter, Randomized, Open-Label Study of
Oral LDK378 Versus Standard Chemotherapy in Adult Patients
with ALK-Rearranged (ALK-Positive) Advanced Non-Small
Cell Lung Cancer Who Have Been Treated Previously with
Chemotherapy (Platinum Doublet) and Crizotinib

Lymphomas
Brentuximab + R-CHOP, 1st Ln DLBCL
A Phase II Study of Brentuximab Vedotin in Combination with
Standard of Care Treatment (Rituximab, Cyclophosphamide,
Doxorubicin, Vincristine, And Prednisone [Rchop]) As Front-
Line Therapy in Patients with Diffuse Large B-Cell Lymphoma

Ovarian, Primary Peritoneal or Fallopian
Tube Cancer
Trabectedin +/- PLD Adv Ovarian 2/3 In
A Randomized, Open-Label Study Comparing the Combination
of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX®
Monotherapy for the Treatment of Advanced-Relapsed
Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Renal Cancer
PRINCIPAL Obs Study of Pazopanib in RCC
PRINCIPAL: A Prospective Observational Study of Real World
Treatment Patterns and Treatment Outcomes in Patients with
Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib

Solid Tumors
CD30 Screening in Solid Tumors and NHL
Screening Protocol to Detect Tumor Antigen Expression
Required for Enrollment on Clinical Research Protocols of
Antibody-Directed Therapy

For more information or to refer a patient, call 888-972-CURE.